Appendixes / Presentations |
Session 1:
Global FMD control through regional co-ordinated actions: opportunities and constraints |
4. Keynote FAO/OIE representative: Global FMD control: opportunities and constraints | 
|
|
5. Global FMDV distribution and regional virus reservoirs: an opportunity to divide and control? |
|
|
6. Hemispheric Program for the Eradication of FMD (PHEFA) Successes and Challenges |
|
|
7. FMD Type C situation – The first target for eradication |
|
|
8. Progress in FMD control in Iran: and perspective on longer term control in the region |
|
|
9. Phylogenetic study of FMDV isolates collected in Russia, CIs-countries and Mongolia in 2000-2007 |
|
|
10. Constraints and opportunities for the control of foot and mouth disease in India |
|
|
11. The global FMD research alliance (GFRA)-an R&D response to the major constraints to global FMD control |
|
|
Vaccination - 2A:
Optimizing programs in a situation of limited resources |
12. Keynote: Vaccination: Overcoming the constraints to achieving effective immunity rates |
|
|
13. Intradermal vaccination with 1/10 dose against FMDV protects pigs as well against clinical disease and subclinical virus shedding as intramuscolar vaccination with a full dose |
|
|
14. Foot-and-mouth disease (FMD) vaccination strategies in sheep and lambs by using commercial oil vaccine |
|
|
15. Longevity of protection in cattle following vaccination with emergency FMD from the UK strategic reserve – Preliminary results |
|
|
Vaccination - 2B:
Overcoming antigenic diversity in simplifying preventive programs |
16. High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus |
|
|
17. Predicting antigenic sites on the FMDV capsid from cross-reactivity data |
|
|
18. Vaccine matching: reliability of foot-and-mouth disease (FMD) r-values determination |
|
|
19. Towards vaccine selection guidelines for each regional virus pool of foot-and-mouth disease |
|
|
Session 2C:
Novel vaccine delivery approaches: progress updates |
20. Expression of FMDV capsid proteins in silkworm-baculovirus expression system and its utilization as an empty Capsid vaccine |
|
|
21. Potential of modified vaccinia Ankara (MOA) as a vaccine delivery vector for foot-and-mouth disease virus (FMDV) |
|
|
22. Marker potential of a vaccine prepared from a foot-and-mouth disease virus with a partial vp1 g-h loop Deletion |
|
|
23. Frenkel lecture: FMD vaccine development - past and future |
|
|
Session 2D:
FMD vaccine standards required for global control |
24. Keynote: Vaccine quality tests, the value of alternative methods? |
|
|
25. A standardized direct contact challenge method for FMDV in swine |
|
|
26. Can in vitro methods reliably replace existing vaccine challenge tests? |
|
|
27. Correlating vaccine induced protection with humoral and cellular immune responses to FMDV: potential in vitro assays for replacement of potency test |
|
|
28. Development of a foot-and-mouth disease vaccine potency test without conducting animal challenge experiment |
| |
Session 3:
Biosecurity and buy-in |
29. Keynote: Biosecurity, what’s in it for me? |
| |
30. Foot-and-mouth disease control in endemic settings: combining epidemiology, risk assessment and value chains analysis to identify risk control points |
|
|
31. Bridging the divide between two bona fide guardians of society’s interests: the disease exterminators and the Sustainable growth advocates |
|
|
32. Keynote: global surveillance for fmd – what are we doing and what could be done |
|
|
Session 4:
Measure progress in global and regional FMD control, and early warning of FMDV emergence |
33. Keynote: Global surveillance of foot-and-mouth disease: concepts, considerations, and requirements |
|
|
34. Sampling, shipping, organisation and testing of inactivated samples to take advantage of molecular analysis Methods |
| |
35. Use of infrared thermography to detect signs of foot–and-mouth disease in wild and domestic ungulates |
| |
36. Sequence identification and genetic profile of FMDV in a 2007 disease outbreak in Israel using full length Genomic analysis |
| |
37. Identification of virulence determinants in FMDV: potential use of functional genomics to predicting viral Pathotypes |
| |
38. The distribution of NSP positive animals in regular vaccinated herds as criterion for effectiveness of vaccine And vaccination during endemic year |
|
|
39. Estimating the vaccination coverage in an FMD free zone-brazil 2005/2006 |
|
|
40. Management of sat-type FMD in southern Africa: present control and trade standards are inappropriate |
|
|
Session 5:
Diagnostics: making quality services available where need |
41. Keynote diagnostics: a new era in access to high performance diagnostics |
|
|
42. Fmd and SVD combined proficiency test studies 2008 – Virological assays |
| |
43. FMD and SVD combined proficiency test scheme studies 2008 (phase xxi) – Serology |
| |
44. Keynote: Driving up global standards for FMD diagnostic, a key role for proficiency testing and international organisations |
|
|
45. An advanced field deployable “pen side” sample preparation and PCR system |
|
|
46. Validation of real-time RT-PCR: matrix effect, uncertainty of measurement and precision |
|
|
47. Development of solid phase competitive ELISAs based on monoclonal antibodies for the serology of FMDV. Serotypes sat1 and sat2 |
|
|
48. Full genome sequencing to support tracing of UK outbreaks of FMD |
|
|
49. Sero-surveillance against foot-and-mouth disease virus (FMDV) non-structural protein antibodies in sheep, Goats and cattle in Jordan after 2006 outbreak |
| |
Parallel Session 5:
Epidemiology |
50. Anticipatory control measures: geographical information systems-based identification of topographic factors Acting as obstacles or disseminators in the 2001 Uruguayan FMD epidemics |
| |
51. Network analysis of livestock movements to estimate potential silent spread of foot-and-mouth disease |
|
|
52. Modelling of FMD outbreaks in The Netherlands: vaccination and regaining the status ‘freedom of infection |
| |
53. Defining the period of infectiousness in cattle naturally infected with foot-and-mouth disease virus |
|
|
54. UK 2001 foot-and-mouth disease epidemic: sequence data and possible airborne spread |
|
|
55. Localisation of foot-and-mouth disease virus after acute infection in cattle; a novel, immunologically significant site |
|
|
56. Investigations into findings of FMD seropositive sheep and goats in Cyprus, an FMD-free country |
|
|
57. Results of molecular testing of samples from Pakistan |
|
|
58. Tracing 2007-2008 emergency episodes of foot-and-mouth disease virus in south America: phylogenetic Analysis |
|
|
59. Sero-prevalence of foot-and-mouth disease in small ruminants under contrasting husbandry practices in Uganda |
|
|
60. The status of foot-and-mouth disease (FMD) in Ethiopia |
|
|
Session 6:
Components and capacity for effective control |
61. Factors influencing global FMD reporting and risk |
|
|
62. Participatory epidemiology as compared to conventional foot and mouth disease surveillance tool |
|
|
63. Development of an improved capability in support of national bio-security for the surveillance and control of Foot-and-mouth disease in cattle and pigs in Viet Nam |
|
|
Parallel Session 6: Diagnostics |
64. Detection of FMDV serotypes o, a and Asia 1 by real-time RT-PCR |
|
|
65. Linear-after-the-exponential (late) PCR: new detection technologies for pan-FMDV and serotype-specific assays In the field |
|
|
66. Evaluation of a lateral flow device for the pen-side diagnosis of foot-and-mouth disease |
|
|
67. Detection of persistently foot-and-mouth disease infected cattle by salivary IGA test |
| |
68. Development and evaluation of IGM ELISA for the detection of FMDV specific IGM antibodies in bovine and ovine sera |
|
|
Session 7:
Prospects for integrating anti-viral approaches |
69. Enhanced prospects for FMDV anti-virals targeted to the 3c protease |
|
|
70. An antiviral agent, t-1105 prevents from virus excretion from pigs infected with porcinophilic foot-and-mouth Disease virus |
| |
Session 8:
Strategy for regional and global control |
71. Elements of a global strategy |
|
|
Poster Session |
72. A foetal goat tongue cell line found highly sensitive for foot-and-mouth disease virus |
| |
73. Epizootiological study of foot-and-mouth disease in the Sudan |
| |
74. Status of foot-and-mouth disease in Pakistan |
| |
75. The relation antibody and protection after foot-and-mouth disease vaccination cannot be standardised |
| |
76. Study of immnunobiologic characteristics |
| |
77. Piglets with maternally derived antibodies can be vaccinated at 2 weeks of age |
| |
78. In vivo and in vitro tests to detect non-structural proteins in foot and mouth disease vaccines |
| |
79. Targeting FMDV minigenes to SLA ii positive cells enhances the induction of cellular responses in swine and Confers protection against viral challenge |
| |
80. Control of foot and mouth disease under public-private partnership (PPP) |
| |
Closed Session |
81. List of participants |
| |
82. Provisional agenda - standing technical committee of the eufmd commission |
| |
83. Item 2: Minimum containment standards for FMD laboratories |
| |
84. Item2.1: Minimum standards of biorisk management for laboratories undertaking diagnostic investigations of low-risk samples during an outbreak of FMD |
| |
85. Item 3 proposed minimum requirements for adoption at the 38th eufmd general session (2009) as a minimum for member states |
| |
86. Options for decentralised diagnosis of secondary cases of foot-and-mouth disease in any future outbreak |
| |
87. Transport of FMDV RNA rather than live virus; optimisation of viral recovery by transfection of infectious RNA |
| |
88. Item 6. Sero-surveillance in Turkey: the question of harmonising the performance/interpretation of sp antibody Data with/between RG member laboratories |
| |
Comments and suggestions: Webmaster